Systemic antifungals

The systemic antifungals market accounts for $3.1bn of the total $41bn anti-infectives market. A wave of new products coinciding with patent expiry of two widely used compounds will shake up the market for systemic infections, further polarizing between winners and losers. Key changes are forcing a rethink of management strategies and clinical trial design.

Over the 2002 to 2006 period, the market for systemic antifungals has risen by a moderate 3.3% from $2.7billion to $3.1 billion; however, its value has dropped by 7.4% between 2005 and 2006.

The US and M5EU launch of the next wave of echinocandins (Eraxis and Mycamine) and the next generation azoles (Vfend and Noxafil) will shorten the current period of devaluation of the market caused by widespread uptake of generic fluconazole and itraconazole.

New diagnostic technology promises to offer clinicians far better decision making tools, emphasizing the need for a rethink of antifungal clinical trial design. Innovative approaches will be needed to ensure that already costly trials do not become prohibitively expensive, while remaining clinically relevant.

Read more...

• The Anti-Infectives Market Outlook to 2013 (14/10/2008)
• Anti-Infectives Market Outlook (14/05/2008)

• Biosimilars regulatory and development issues (20/05/2008)
• Monoclonal Antibodies Report Part II (19/05/2008)
• Acute Stroke (19/05/2008)

• NNRTIs (16/05/2008)
• Non-Hodgkin's Lymphoma (16/05/2008)
• Multiple Myeloma (16/05/2008)
• Innovation in Drug Delivery (15/05/2008)
• Next-Generation Nutraceuticals (15/05/2008)
• Innovations in CNS (15/05/2008)
• Protein Engineering & Drug Design (14/05/2008)
• Winning Product Launch Strategies (14/05/2008)
• Drug Repositioning Strategies (14/05/2008)

---